Gao et al. (2022) reported that the upregulation of ANGPTL4 was associated with podocyte damage in DKD mice. Under HG conditions, ANGPTL4 overexpression in vitro counteracted the protective effects of ManNAc against podocyte injury via the ROS/NLRP3 signaling pathway. Similarly, ANGPTL4 upregulation activated the integrin-β1/FAK signaling pathway, promoting podocyte apoptosis and actin cytoskeletal disruption, which could be reversed by ANGPTL4-neutralizing antibodies or ManNAc supplementation (Guo et al., 2020). Here, ANGPTL4 is linked to diabetic kidney disease.